风险分层和早期干预在燃烧的多发性骨髓瘤
Manraj Singh Sra1, Shaji Kumar1
1Division of Hematology, Mayo Clinic, Rochester, MN, USA.
Leukemia & lymphoma
|October 24, 2025
概括
燃烧的多发性骨髓瘤 (SMM) 是多发性骨髓瘤 (MM) 的前体,具有不同的进展风险. 本综述涵盖了风险模型,早期治疗证据和对高风险SMM患者的持续研究.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 临床研究 临床研究
背景情况:
- 燃烧多发性骨髓瘤 (SMM) 是多发性骨髓瘤 (MM) 的前体.
- SMM是生物多样性的,具有不同的进展风险.
- 风险分层模型可以识别那些可能受益于早期干预的高风险患者.
研究的目的:
- 审查目前的SMM风险分层模型.
- 总结临床试验中关于高风险SMM早期治疗策略的证据.
- 突出正在进行的研究和关于早期干预的长期益处的不确定性.
主要方法:
- 对SMM当前风险分层模型的文献综述.
- 关于SMM预防策略的关键临床试验数据的摘要.
- 讨论中小企业管理领域不断发展的研究.
主要成果:
- 有验证的风险模型存在,以识别高风险的SMM.
- 目前的指导方针建议在高风险的SMM中使用基于lenalidomide的疗法或daratumumab单疗法.
- 关于长期生存和生活质量益处的不确定性仍然存在.
结论:
- 早期干预高风险SMM受到当前指导方针和新出现的数据的支持.
- 需要进一步的研究来澄清早期治疗的长期风险/益处比率.
- 随着SMM研究的不断发展,SMM研究提供了对前体管理的新见解.
相关概念视频
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K


